Evidence map›Paper›PMID 31250122›Full record

ReviewCurrent diabetes reports2019

Fecal Microbiota Transplantation: a Future Therapeutic Option for Obesity/Diabetes?

Judith Aron-Wisnewsky, Karine Clément, Max Nieuwdorp

Registry-linked trialOpen access · greenAbstract readReview
PubMed Publisher
In one paragraph

Review in Current diabetes reports, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04698135 (Costituzione Della Biobanca Del Microbiota Intestinale e Salivare Umano), which is not on this map. Cited by 85 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
85citing papers in PubMed, 1 pooled it
10.7field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04698135 completednot on this mapstarted 2021, after this paper: background citation

Costituzione Della Biobanca Del Microbiota Intestinale e Salivare Umano: Dalla Disbiosi Alla Simbiosi

TypeobservationalSponsorAzienda Ospedaliero-Universitaria Consorziale Policlinico di BariRan2021 to 2022Enrolled59ConditionsMorbid Obesity, Metabolically Healthy ObesityArmsBiological samples collection, Questionnaire, Medical/laboratory examinations
3 · Its place in the literature

Who cites it

85 citing papers in PubMed, 1 synthesis or guideline pooled it, 142 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Trial
  4. Trial
  5. Review
  6. Article
  7. Article
  8. Review
  9. Review
  10. The Genetic Blueprint of Obesity: From Pathogenesis to Novel Therapies.Obesity reviews : an official journal of the International Association for the Study of Obesity · 2025
    Review
  11. Review
  12. Article
  13. Article
  14. Review
  15. Article
  16. Review
  17. Article
  18. Review
  19. Observational
  20. Review

25 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 2 countries.

Judith Aron-WisnewskySorbonne Université, INSERM, Nutrition and Obesities: Systemic Approaches (NutriOMics) Research Unit, Paris, France. judith.aron-wisnewsky@psl.aphp.fr.
Karine ClémentSorbonne Université, INSERM, Nutrition and Obesities: Systemic Approaches (NutriOMics) Research Unit, Paris, France.
Max NieuwdorpAmsterdam UMC, Location AMC and VUMC, Department of Internal and Vascular Medicine, University of Amsterdam, Amsterdam, The Netherlands.
Nutrition et obésité : approches systémiques · FRUniversity of Amsterdam · NL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purpose of reviewThe aim of this review is to summarize the current data available on the metabolic effects of fecal microbiota transplantation (FMT) including obesity and glucose metabolism in humans. RECENT

findingsGut microbiota dysbiosis is a frequent characteristic observed in obesity and related metabolic diseases. Pieces of evidence mostly generated in mouse models suggest that rescuing this dysbiosis associates with improved metabolism. In humans, dietary or bariatric surgery interventions are often accompanied by complete or partial restoration of this dysbiosis together with weight reduction and metabolic amelioration. FMT is an interesting option to modify gut microbiota and has been associated with improved clinical outcomes, albeit only used in routine care for Clostridium difficile infection. However, there are only limited data on using FMT in the metabolic context. FMT from lean donors significantly improves insulin sensitivity in obese subjects with metabolic syndrome. However, there is a wide range of clinical responses. Interestingly in subjects with high microbial gene richness at baseline and when FMT donors that are metabolically compromised are used, no metabolic improvement is seen. Moreover, more studies evaluating the effect of FMT in patients with overt type 2 diabetes are warranted. Furthermore, interventions (in the receiver prior to FMT) aiming to enhance FMT response also need evaluation.

Indexed as

Clostridium InfectionsDiabetes MellitusFecal Microbiota TransplantationAnimalsFecesHumansObesityTreatment OutcomeEncapsulated fecesFecal microbiota transplantationMicrobiotaObesityType 2 diabetes

Identifiers

PMID31250122
OpenAlexW2956018562

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.